Please type a plus sign (+) inside this box [+]

PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	09/833,526
Filing Date	April 11, 2001
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HUYNH, Phuong N.
Attorney Docket Number	A-68983-1/RFT/RMS/RMK

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PNH	1.	ANASETTI et al., "Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody", Transplantation 54:844-851 (1992)	
	2.	ASANO M, et al., "Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation." J Exp Med. 1996 Aug 1;184(2):387-96.	
	3.	BARKER et al., "Identification of multiple and distinct CD8+ T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to gamma irradiation," J Immunol 156:4476-4483 (1996)	
	4.	BLAZAR et al., "Both CD4+ and CD8+ T Cells Can Cause Accelerated GVHD Lethality in the Presence of High In Vivo Doses of Exogenous Il10: Role of Interfereon Gamma (IFNγ) in GVHD Induction, Blood 88:247 (1996) (abstract)	
	5.	BLAZAR et al., "FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation", J. Immunol 153:1836-1846 (1994)	
	6.	BLAZAR et al., "Murine recipients of fully mismatched donor marrow are protected form lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome", J. Immunol 151:5726-5741 (1993)	
	7.	BLAZAR et al., "Recent advances in graft-versus-host disease (GVHD)", Immunol Rev 157:79-90 (1997)	
	8.	BONINI et al., "HSY-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science 276:1719-1724 (1997)	
✓	9.	BORDER et al., "Transforming growth factor-beta in disease: the dark side of tissue repair," J Clin Invest 90:1-7 (1992)	

Examiner Signature		Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+] PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known	
Application Number	09/833,526
Filing Date	April 11, 2001
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HUYNH, Phuong N.
Attorney Docket Number	A-68983-1/RFT/RMS/RMK

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PNH	10.	BOUSSIOTIS et al., "B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specif tolerance," J Exp Med 178:1753-1763 (1993)	
	11.	CHANDRASEKAR, B., et al., "Dietary calorie restriction inhibits transforming growth factor-beta (TGF- beta) expression in murine lupus nephritis", 9th International Congress on Immunology, 848 (1995)	
	12.	CHAVIN et al., "Anti-CD2 mAbs Suppress Cytotoxic Lymphocyte Activity by the Generation of Th2 Suppressor Cells and Receptor Blockade," J Immunol 152:3729-3739 (1994)	
	13.	CHONG P. et al. "Inhibition of protein-kinase C in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: effect on spontaneous immunoglobulin production," Autoimmunity, 10:227-231 (1991)	
	14.	DELGIUDICE, G., et al., "TGF-beta activity is increased in systemic lupus erythematosus (SLE) and progressive systemic sclerosis (PSS)", Arthritis and Rheumatism Vol. 36 (9 Suppl.) p S196(Sept. 1993)	
	15.	DUMONT et al., "Distinct Mechanisms of Suppression of Murine T Cell Activation by the Related macrolides FK-506 and Rapamycin", J. Immunol 144:251-258 (1990)	
	16.	DUPONT, B., "Immunology of hematopoietic stem cell transplantation: a brief review of its history", Immunol Reviews 157:5-12 (1997)	
	17.	FAST, "Generation and characterization of IL-2-activated veto cells", J Immunol 149:1510-1515 (1992)	
	18.	FERNANDES, G., et al., "Calorie restriction delays autoimmune murine lupus by differentially modulating oncogenes and TGF- beta-1 expression", 9th International Congress on Immunology., 848 (1995).	
	19.	FOWLER et al., "Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice", Blood 84:3540-3549 (1994)	
	20.	GAO Q, et al., "CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice." Transplantation. 1999 Dec 27;68(12):1891-7.	
	21.	GOLDMAN et al., "Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion", Ann Intern Med 108:806-814 (1988)	
	22.	GRATAMA et al., "Treatment of Acute Graft-Versus-Host Disease With Monoclonal Antibody OKT3. Clinical results and effect on circulating T lymphocytes", Transplantation 38(5):469-474 (1984)	
	23.	GRAY et al., "Activated Natural Killer Cells Can Induce Resting B Cells to Produce Immunoglobulin," Arthritis & Rheumatism, 37(9)suppl:S378 (1994)	
	24.	GRIBBEN et al., "Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool", Blood 97:4887-4893 (1996)	
	25.	HAHN, B.H., Dubois'Lupus Erythematosus, 5th Ed. (1997), pp. 69-76 (D.J. Wallace et al. eds., Williams and Wilkins, Baltimore)	
	26.	HERVE et al., "Treatment of Corticosteroid Resistant Acute Graft-Versus-Host Disease by In Vivo Administration of Anti-Interleukin-2 Receptor Monoclonal Antibody (B-B10)", Blood 75(4):1017-1023 (1990)	
	27.	HIROHATA et al., "Role of Il-2 in the generation of CD4+ suppressors of human B cell responsiveness", J Immunol 142:3104-3112 (1989)	

Examiner Signature		Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+] PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known	
Application Number	09/833,526
Filing Date	April 11, 2001
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HUYNH, Phuong N.
Attorney Docket Number	A-68983-1/RFT/RMS/RMK

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PNH	28.	HIROKAWA et al., "Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation", J. Immunol. 149:1859-1866, 1992	
	29.	HIRUMA et al., "Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space", Blood 79:3050-3058 (1992)	
	30.	HORWITZ DA, et al., "Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus." Arthritis Rheum. 1998 May;41(5):838-44.	
	31.	HORWITZ, D. A., et al., "The immunoregulatory effects of NK cells: the role of TGF-β and implications for autoimmunity", Immunology Today, Vol. 18(11):538-542 (Nov. 1997).	
	32.	HORWITZ, D.A., Dubois'Lupus Erythematosus, 5th Ed. (1997), pp. 155-194 (D.J. Wallace et al. eds., Williams and Wilkins, Baltimore)	
	33.	HUGGINS, M. L., et al., "Modulation of the Autoimmune Response in Lupus Mice by Oral Administration of Attenuated Salmonella typhimurium Expressing the IL-2 and TGF-β Genes", Annals of New York Acad. of Sciences, Vol. 815:499-502 (1997)	
	34.	JACKSON AL, et al., "Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells." Clin Immunol Immunopathol. 1990 Jan;54(1):126-33.	
	35.	KANEGANE H, et al., "A novel subpopulation of CD45RA+ CD4+ T cells expressing IL-2 receptor alpha-chain (CD25) and having a functionally transitional nature into memory cells." Int Immunol. 1991 Dec;3(12):1349-56.	
	36.	KINTER et al., "Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to simulate virus expression", Proc. Natl. Acad. Sci. USA 92:10985-10989 (1995)	
	37.	KLINMAN DM, et al., "Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus." Arthritis Rheum. 1991 Nov;34(11):1404-10.	
	38.	KRENGER et al., "Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens", Transplantation 58:1251-1257 (1994)	
	39.	KRENGER et al., "Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease", J Immunol 153:585-593 (1995)	
	40.	LINKER-ISRAELI M, et al., "CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis." Arthritis Rheum. 1990 Aug;33(8):1216-25.	
	41.	LUCAS et al., "The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation", Blood 87:2594-2603 (1996)	
	42.	MARTIN et al., "Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts", Blood 66:664-672 (1985)	
	43.	MARTIN et al., "Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease", Bone Marrow Transplant 3:437-444 (1989)	
	44.	MARTIN, "Overview of Marrow Transplantation Immunology", in Bone Marrow Transplantation (eds. Forman et al.) pp. 16-21, Boston, Blackwell Scientific Publications (1994)	
✓	45.	MARTIN, P.J. et al., "Treatment of Acute Graft-Versus-Host Disease with Anti-CD3 Monoclonal Antibodies," Am Jour Kidney Disease 11(2):149-152 (1988)	

Examiner Signature		Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+] PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known	
Application Number	09/833,526
Filing Date	April 11, 2001
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HUYNH, Phuong N.
Attorney Docket Number	A-68983-1/RFT/RMS/RMK

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PNH	46.	MASSAGUE J., "The transforming growth factor-beta family." Annu Rev Cell Biol. 1990;6:597-641.	
	47.	MASSAGUE, "Receptors for the TGF-bata family", Cell 69:1067-1070 (1992)	
	48.	MORRIS, "Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action", Ann NY Acad Sci 685:68-72 (1993)	
	49.	MURPHY et al, "The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation," Immunol Rev 157:167-176 (1997)	
	50.	OHTSUKA, K., et al., "Decreased Production of TGF-β by Lymphocytes from Patients with Systemic Lupus Erythematosus", J. Immunol. 160:2539-2545 (1998).	
	51.	OSWALD, et al., "IL-10 Synergizes with IL-4 and Transforming Growth Factor-Beta to Inhibit macrophage Cytotoxic Activity," J Immunology 148(11):3578-3582 (1992)	
	52.	PAPIERNIK M, et al., "T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity." J Immunol. 1997 May 15;158(10):4642-53.	
	53.	PATTERSON et al., "Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation", Br J Haematol 63:221-230 (1986)	
	54.	POWRIE F, et al., "A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells." J Exp Med. 1996 Jun 1;183(6):2669-74.	
	55.	READ S, et al., "Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation." J Exp Med. 2000 Jul 17;192(2):295-302.	
	56.	RODT, H., "Anti-lymphocytic antibodies and marrow transplantation. 3. Effect of heterologous anti-brain antibodies on acute secondary disease in mice", Eur. J. Immunol 4:25-29 (1974)	
	57.	SAKAGUCHI S, et al., "Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease." J Exp Med. 1985 Jan 1;161(1):72-87.	
	58.	SHIVAKUMAR S, et al., "T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis." J Immunol. 1989 Jul 1;143(1):103-12.	
	59.	SPORN et al., "Some recent advances in the chemistry and biology of transforming growth factor-beta," J Cell Biol 105:1039-1045 (1987)	
	60.	STORB et al., "Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia", Blood 80:560-561 (1992)	
	61.	STRAND, V., "Approaches to the management of systemic lupus erythematosus," Current Opinion in Rheumatology, 9:410-420 (1997)	
	62.	SULLIVAN et al., "Chronic Graft-Versus-Host Disease and Other Late Complications of Bone Marrow Transplantation", Semin Hematol 28:250-259 (1992)	
✓	63.	SURI-PAYER E, et al., "CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells." J Immunol. 1998 Feb 1;160(3):1212-8.	

Examiner Signature		Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box [+] PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known	
Application Number	09/833,526
Filing Date	April 11, 2001
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HUYNH, Phuong N.
Attorney Docket Number	A-68983-1/RFT/RMS/RMK

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PNH	64.	SURI-PAYER E, et al., "Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells." Eur J Immunol. 1999 Feb;29(2):669-77.	
	65.	TAKAHASHI T, et al., "Human CD8+ lymphocytes stimulated in the absence of CD4+ cells enhance IgG production by antibody-secreting B cells." Clin Immunol Immunopathol. 1991 Mar;58(3):352-65.	
	66.	TAKAHASHI T, et al., "Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state." Int Immunol. 1998 Dec;10(12):1969-80.	
	67.	TAYLOR, "Antigen specific suppressor T cells respond to cytokines released by T cells", Advances Exp Med Biol 319:125-135 (1992)	
	68.	THORNTON AM and Shevach EM. "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production." J Exp Med. 1998 Jul 20;188(2):287-96.	
	69.	THORNTON AM and Shevach EM. "Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific." J Immunol. 2000 Jan 1;164(1):183-90.	
	70.	VALLERA et al., "Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone", Transplantation 31:218-222 (1981)	
	71.	VIA et al., "Critical Role of interleukin-2 in the development of acute graft-versus-host disease", International Immunol 5:565-572 (1993)	
	72.	WAHL SM. "Transforming growth factor beta: the good, the bad, and the ugly." J Exp Med. 1994 Nov 1;180(5):1587-90.	
	73.	WEINER HL, et al., "Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens." Annu Rev Immunol. 1994;12:809-37	
✓	74.	ZELLER, et al., "Ex vivo IL10 and TGF-Beta Act Synergistically to Induce CD4+ Alloantigen-Specific Tolerance Resulting in Diminished Graft-Versus-Host Disease in Vivo," FASEB Journal (March 12, 1999) 12(4)part 1, A614. Meeting Info: Annual Meeting of the Professional Research Scientists for Experimental Biology. April 17-21 1999.	

Examiner Signature	Phuong N. Huynh	Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Unique citation designation number. [2] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.